Register

Hematology

Vascular Neurology   

Questions discussed in this category

How would you manage a CVST secondary to a traumatic brain injury with the presence of intracranial hemorrhage?
When would you consider using anticoagulation and for how long?
4 Answers available
Does aspirin dose (81 mg vs 325 mg) matter for secondary stroke prevention?
Should some patients get 325 mg instead of 81mg at least for a certain amount of time, such as patients in the acute phase of ischemic stroke or patie...
1 Answer available
Do you screen adults in your practice with sickle cell disease for silent cerebral infarcts?
The ASH 2020 guidelines have "recommended that adults with HbSS or HbSβ0 thalassemia be screened at least once for silent cerebral infarcts even ...
1 Answer available
Do you typically use NOACs or Lovenox in patients with stroke due to hypercoagulability from malignancy?
1 Answer available
Would you change an elderly, frail patient with atrial fibrillation who is already on a NOAC to VKA treatment?
In FRAIL-AF, switching VKA therapy to a NOAC was associated with higher risk of bleeding in elderly, frail patients. 
4 Answers available
Do you consider bleeding risk in elderly, frail patients with atrial fibrillation to be similar for all NOACs?
In FRAIL-AF, participants were switched from VKA to dabigatran, rivaroxaban, apixaban, and edoxaban.
2 Answers available
Do you think that home INR monitoring is a feasible option for elderly, frail patients with atrial fibrillation on VKA treatment, given variations in socioeconomic status and access to care?
2 Answers available
In antiphospholipid syndrome with recurrent strokes, would you consider adding antiplatelets to warfarin?
Also how would you manage this perioperatively?
7 Answers available
Would you start anticoagulation in a patient with a history of CVA 1 year ago and high risk APL profile who was never started on anticoagulation, but is now presenting for follow up and without recurrent thrombotic events?
The patient has no known history of autoimmune disease.
4 Answers available
What additional testing besides LAC/APLS, factor V Leiden, prothrombin gene mutation, JAK 2 do you draw for unprovoked cerebral venous sinus thrombosis?
1 Answer available
Is there a role to continue aspirin in patients with myeloproliferative disorders who have never had a thrombotic event that are starting DOAC for stroke prophylaxis with newly diagnosed atrial fibrillation?
2 Answers available
How would you manage anti-platelet therapy in patients presenting with ischemic stroke and have a history of von Willebrand disease?
1 Answer available
How will you treat a young man with recurrent cryptogenic strokes with no identifiable cause, with MTHFR A1298C homozygous mutation and normal homocysteine level?
1 Answer available
Do you typically recommend four factor prothrombin complex concentrate versus fresh frozen plasma for INR correction in patients with vitamin K antagonist associated spontaneous ICH?
4 Answers available
What is the recommended management approach in regard to diagnostic evaluation and treatment for patients with homocystinuria and cerebral thrombosis?
Do we prophylactically place patients on anticoagulation after one episode? Besides MRI/MRV brain, are there other diagnostic imaging that should b...
1 Answer available
How would you approach protein S deficiency found on hypercoagulability work-up in a patient with a post-operative central retinal vein occlusion?
In the setting of no personal or family history and no other risk factors for thrombosis, is systemic anticoagulation warranted if local treatments (e...
4 Answers available
How long after starting anticoagulation would you remove an IVC filter in a patient with a DVT presenting with stroke and PFO which is now closed?
1 Answer available
What is your approach to a patient who has an ischemic stroke while on clopidogrel despite strict compliance and normal results on clopidogrel response assay?
5 Answers available
How does evidence of cerebral amyloid angiopathy/microbleeds affect choices for secondary stroke prevention in patients with a history of ischemic stroke and atrial fibrillation?
How do you approach secondary stroke prevention for patients with ischemic stroke, atrial fibrillation, and signs of cerebral amyloid angiopathy/micro...
1 Answer available
Is antiplatelet or anticoagulant therapy preferred for the secondary prophylaxis of cryptogenic stroke in a patient with underlying malignancy?
4 Answers available


Papers discussed in this category

American journal of hematology, 2023 May 12
An integrated therapeutic approach to sickle cell disease management beyond infancy.
The New England journal of medicine, 2014 Aug 21
More blood for sickle cell anemia?
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2019-08
Treatment Approaches to Lacunar Stroke.
Stroke, 2021 Sep 14
Cilostazol for Secondary Stroke Prevention: History, Evidence, Limitations, and Possibilities.
Stroke, 2015-03
Outcome in patients previously on antithrombotic therapy in the SAMMPRIS trial: subgroup analysis.
BMJ open, 2014-12-02
Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study.
J Am Heart Assoc, 2020 Nov 23
Direct Oral Anticoagulants in Patients With Inherited Thrombophilia and Venous Thromboembolism: A Prospective Cohort Study.
Am J Hematol,
Protein S abnormalities: a diagnostic nightmare.
Cancer causes & control : CCC, 2010-03
Germline polymorphisms in the one-carbon metabolism pathway and DNA methylation in colorectal cancer.
Atherosclerosis, 2001-06
The 1298A-->C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine.
The American journal of clinical nutrition, 2008-10
Associations between single nucleotide polymorphisms in folate uptake and metabolizing genes with blood folate, homocysteine, and DNA uracil concentrations.
Circulation. Cardiovascular genetics, 2008-12
Variants of folate metabolism genes and the risk of conotruncal cardiac defects.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2012-01
Methylenetetrahydrofolate reductase (MTHFR) polymorphism A1298C (Glu429Ala) predicts decline in renal function over time in the African-American Study of Kidney Disease and Hypertension (AASK) Trial and Veterans Affairs Hypertension Cohort (VAHC).
Human genetics, 2012-05
Strong protective effect of the aldehyde dehydrogenase gene (ALDH2) 504lys (*2) allele against alcoholism and alcohol-induced medical diseases in Asians.
PeerJ, 2013
Integrating precision medicine in the study and clinical treatment of a severely mentally ill person.
Nature, 2016-08-18
Analysis of protein-coding genetic variation in 60,706 humans.
Am J Hum Genet, 1998 May
A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?
Am J Reprod Immunol, 2011 Jan 18
Analysis of plasminogen activator inhibitor-1, integrin beta3, beta fibrinogen, and methylenetetrahydrofolate reductase polymorphisms in Iranian women with recurrent pregnancy loss.
Am J Reprod Immunol, 2012 Aug 06
Plasminogen activator inhibitor 1 and methylenetetrahydrofolate reductase gene mutations in iranian women with polycystic ovary syndrome.
BMC Cancer, 2008 Nov 07
Low-penetrance alleles predisposing to sporadic colorectal cancers: a French case-controlled genetic association study.
BMJ Case Rep, 2012 Nov 15
Neonatal stroke associated with de novo antiphospholipid antibody and homozygous 1298C/C methylenetetrahydrofolate reductase mutation.
BMJ Case Rep, 2013 Jun 13
Bilateral consecutive optic neuropathy in a patient with thrombophilia.
Mol Biol Rep, 2010 Jun 08
The association between methylene-tetrahydrofolate reductase gene polymorphism and lung cancer risk.
Mol Biol Rep, 2010 Nov 16
Association of deep venous thrombosis with prothrombotic gene polymorphism identified in lung cancer cases.
Nat Genet, 2008 Jul
Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database.
Proc Natl Acad Sci U S A, 2001 Mar 13
Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia.
Mol Biol Rep, 2018 Mar 29
CBS mutations and MTFHR SNPs causative of hyperhomocysteinemia in Pakistani children.
Transfus Apher Sci, 2014 Jan 08
Association of methylenetetrahydrofolate reductase (A1298C and C677T) polymorphisms with retinal vein occlusion in Tunisian patients.
J Matern Fetal Neonatal Med, 2015 Jul 02
Thrombophilic genes alterations as risk factor for recurrent pregnancy loss.
Clin Neurol Neurosurg, 2013 Mar 21
Association of methylenetetrahydrofolate reductase A1298C polymorphism but not of C677T with multiple sclerosis in Tunisian patients.
J Hum Genet, 2006 Feb 18
MTHFR C677T and A1298C polymorphisms are risk factors for Down's syndrome in Indian mothers.
Arthritis and rheumatism, 2007-07
Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals.
Stroke, 2014-07
Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.
Cochrane Database Syst Rev, 2020 Oct 12
Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
Archives of internal medicine, 1997-10-13
A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis.
Lupus, 2011-02
Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies.
Annals of the rheumatic diseases, 2019-10
EULAR recommendations for the management of antiphospholipid syndrome in adults.
,
Diagnosis and Management of the Antiphospholipid Syndrome.
Lupus,
16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends.
Stroke, 2021 May 24
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association.
J Autoimmun, 2018 Feb 13
The treatment of anti-phospholipid syndrome: A comprehensive clinical approach.
Int J Med Sci, 2009 Dec 05
Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome.
Blood Adv,
ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease.
The New England journal of medicine, 2018-02-15
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
N Engl J Med, 2020 Mar 29
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
N Engl J Med, 2003 Jul 10
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
J Clin Med, 2020 Mar 10
Cerebral and Splanchnic Vein Thrombosis: Advances, Challenges, and Unanswered Questions.
Hematology Am Soc Hematol Educ Program, 2021 Dec 10
Clots in unusual places: lots of stress, limited data, critical decisions.
JAMA Neurol, 2019 Dec 01
Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial.
Circulation, 2023 Aug 27
Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial.

Related Topics in Hematology

Copyright © 2024 theMednet
All Rights Reserved.